Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Depreciation & Amortization (CF) (2016 - 2025)

Mimedx's Depreciation & Amortization (CF) history spans 15 years, with the latest figure at $572000.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 1.42% year-over-year to $572000.0; the TTM value through Dec 2025 reached $1.1 million, down 50.0%, while the annual FY2025 figure was $14.9 million, 146.33% up from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $572000.0 at Mimedx, up from $558000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $1.3 million in Q2 2021 and bottomed at $558000.0 in Q1 2024.
  • The 5-year median for Depreciation & Amortization (CF) is $700500.0 (2023), against an average of $764611.1.
  • The largest annual shift saw Depreciation & Amortization (CF) crashed 41.06% in 2021 before it rose 1.42% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $973000.0 in 2021, then decreased by 18.19% to $796000.0 in 2022, then decreased by 23.24% to $611000.0 in 2023, then decreased by 7.69% to $564000.0 in 2024, then grew by 1.42% to $572000.0 in 2025.
  • Per Business Quant, the three most recent readings for MDXG's Depreciation & Amortization (CF) are $572000.0 (Q4 2025), $558000.0 (Q2 2025), and $564000.0 (Q4 2024).